Nucleic acid molecules comprising a mutation that mutation modulates the interaction strength of the nucleic acid molecule to a 16S ribosomal RNA are provided. Methods of improving the translation process of a nucleic acid molecule and producing a nucleic acid molecule optimized for translation, as well as cells comprising the nucleic acid molecules are also provided.

Predictive engineering of a sample derived from a genetically optimized non-human donor suitable for xenotransplantation into a human having improved quality or performance is described. A training data set is constructed from a series of libraries, including at least one library comprising genomic, proteomic, and research data specific to non-humans. A predictive machine learning model is developed based on the constructed training data set and utilized to obtain a predicted quality or performance of a plurality of sequences for a candidate sample from the non-human donor specific to a human patient or patient population. A subset of sequences is selected for evaluation from the plurality of sequences based on the predicted quality or performance and candidate samples are designed derived from the non-human donor using the selected subset of sequences.

A system for predicting prime editing efficiency by using deep learning, including: an information input unit that receives an input of data on prime editing efficiency of a prime editor, a predictive model generator for generating prime editing efficiency predictive models by performing deep learning to learn a relationship between features affecting prime editing efficiency and prime editing efficiency, by using the data received from the information input unit, a candidate sequence input unit that receives an input of a candidate target sequence for prime editing; and an efficiency predictor for predicting prime editing efficiency by applying the candidate target sequence input into the candidate sequence input unit to an efficiency predictive model generated in the predictive model generator.

Systems and methods for assessing mRNA in vivo and/or in vitro stability are disclosed. Some embodiments methods obtain RNA indexed or barcoded RNA molecules which are then tested against various conditions including stability inside of cells, stability in cell lysate, and stability in solution (e.g., for storage and/or transportation). Additional embodiments describe methods to determine degradation points with single base resolution.

The present invention provides a system for receiving biological sequence information and activating the synthesis of a biological entity. The system has a receiving unit for receiving a signal encoding biological sequence information transmitted from a transmitting unit. The transmitting unit can be present at a remote location from the receiving unit. The system also has an assembly unit connected to the receiving unit, and the assembly unit assembles the biological entity according to the biological sequence information. Thus, according to the present invention biological sequence information can be digitally transmitted to a remote location and the information converted into a biological entity, for example a protein useful as a vaccine, immediately upon being received by the receiving unit and without further human intervention after preparing the system for receipt of the information. The invention is useful, for example, for rapidly responding to viral and other biological threats that are specific to a particular locale.

Synthetic RNA molecules comprising at least two first RNA-binding protein (RBP)-binding motifs, at least two second RBP-binding motifs and at least two third RBP-binding motifs, wherein the at least two first RBP-binding motifs bind the same first RBP and comprise non-identical sequences are provided. Synthetic RNA molecules comprising at least two RBP-binding motifs, a regulatory element and an open reading frame wherein the RBP-binding motifs individually repress translation and cooperatively enhance translation of the open reading frame are also provided. Methods employing machine learning models to determine variant sequence binding to RBPs are also provided.

Provided herein are compositions, devices, systems and methods for the generation and use of biomolecule-based information for storage. Additionally, devices described herein for de novo synthesis of nucleic acids encoding information related to the original source information may be rigid or flexible material. Further described herein are highly efficient methods for long term data storage with 100% accuracy in the retention of information. Also provided herein are methods and systems for efficient transfer of preselected polynucleotides from a storage structure for reading stored information.

The disclosure provides methods and systems for designing and synthesizing probes to capture a representative sample of genomic variants of a target genome from a sample. The methods include providing a multiple sequence alignment (MSA), designing a plurality of representative subsequences, and optionally synthesizing a nucleic acid probe. The designing step can comprise designating a plurality of intervals in the MSA, shifting start positions for each MSA subset, clustering the aligned subsequences within each adjusted subset, and determining a representative sequence for each reduced MSA subset. The disclosure also encompasses methods of isolating a plurality of nucleic acid variants of a targeted genomic subregion from a sample using the disclosed probe design, as well as the probe compositions themselves.

Processes and materials to detect cancer from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences derived from a neoplasm. Detection of somatic variants occurring in phase can indicate the presence of cancer in a diagnostic scan and a clinical intervention can be performed.

Systems and methods for assessing mRNA in vivo and/or in vitro stability are disclosed. Some embodiments methods obtain RNA indexed or barcoded RNA molecules which are then tested against various conditions including stability inside of cells, stability in cell lysate, and stability in solution (e.g., for storage and/or transportation). Additional embodiments describe methods to determine degradation points with single base resolution.